Active Ingredient
Ceftriaxone Sodium equivalent to Ceftriaxone 250mg per vial for intravenous administration
What Oxidil IV Injection 250mg Is Used For
Oxidil IV Injection 250mg contains ceftriaxone sodium, a third-generation cephalosporin antibiotic administered intravenously for the treatment of serious and severe bacterial infections in adults and children where rapid achievement of high systemic antibiotic concentrations is clinically necessary. Intravenous administration ensures immediate and complete bioavailability, making this formulation particularly appropriate for severe, life-threatening, or deep-seated infections where oral or intramuscular therapy is insufficient or not feasible. This medication is indicated for:
- Lower respiratory tract infections including severe community-acquired pneumonia, hospital-acquired pneumonia, empyema, and lung abscess caused by susceptible bacterial organisms
- Serious skin and soft tissue infections including severe cellulitis, necrotizing fasciitis requiring systemic antibiotic support alongside surgical management, infected diabetic foot ulcers, and deep wound infections
- Kidney infections including complicated pyelonephritis and renal abscess where high and sustained antibiotic concentrations in renal tissue are required for effective treatment
- Complicated urinary tract infections including those caused by resistant organisms or associated with structural urinary tract abnormalities where oral therapy has failed or is not appropriate
- Bacterial septicemia, a life-threatening condition in which bacteria and their toxins are present in the bloodstream causing systemic inflammatory response and risk of septic shock and multi-organ failure
- Meningitis and central nervous system infections caused by susceptible organisms, where ceftriaxone's ability to achieve therapeutic concentrations in cerebrospinal fluid makes it a drug of choice
- Intra-abdominal infections including peritonitis and biliary tract infections in combination with appropriate anaerobic coverage
- Bone and joint infections including osteomyelitis and septic arthritis requiring parenteral antibiotic therapy
- Pelvic inflammatory disease and other serious gynecological infections
- Febrile neutropenia as part of empirical broad-spectrum antibiotic coverage
- Surgical prophylaxis before high-risk procedures where parenteral coverage is required
Ceftriaxone is a bactericidal antibiotic that works by binding to and irreversibly inactivating penicillin-binding proteins located on the inner membrane of bacterial cell walls. This disrupts the final transpeptidation step in peptidoglycan synthesis, the structural polymer essential for bacterial cell wall integrity, causing progressive weakening of the cell wall and ultimately osmotic lysis and bacterial death. Ceftriaxone demonstrates broad-spectrum bactericidal activity against a wide range of clinically important gram-positive organisms including Streptococcus pneumoniae and Streptococcus pyogenes, and gram-negative organisms including Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and Neisseria gonorrhoeae. Its resistance to many beta-lactamases produced by gram-negative bacteria provides activity against organisms that are resistant to earlier generation cephalosporins and penicillins. The intravenous route ensures immediate achievement of peak plasma concentrations, which is critical in severe infections and septicemia where delays in achieving therapeutic drug levels can directly affect patient survival. Ceftriaxone's long plasma half-life of approximately 6-8 hours in adults with normal renal and hepatic function supports once or twice daily dosing, simplifying administration and supporting antibiotic stewardship principles.
Important Safety Information
Who Should NOT Receive Oxidil IV Injection 250mg
Do not administer this medication to patients who have a known hypersensitivity or anaphylactic reaction to ceftriaxone, any other cephalosporin antibiotic, or any excipients in the intravenous formulation, have a history of severe immediate hypersensitivity reaction to penicillin antibiotics as clinically significant cross-reactivity between penicillins and cephalosporins exists, are neonates aged 41 weeks corrected gestational age or younger, are hyperbilirubinemic neonates or premature infants as ceftriaxone displaces bilirubin from albumin binding sites and can cause life-threatening bilirubin encephalopathy, require concurrent administration of calcium-containing intravenous solutions as the combination produces insoluble ceftriaxone-calcium precipitates that can cause fatal pulmonary and renal complications, particularly in neonates where this combination is absolutely contraindicated regardless of the route or timing of administration, or have no confirmed or strongly suspected bacterial infection requiring parenteral third-generation cephalosporin therapy.
Serious Warnings and Precautions
Anaphylaxis and Severe Hypersensitivity Reactions: Serious and potentially fatal hypersensitivity reactions including anaphylaxis, anaphylactic shock, severe bronchospasm, angioedema, and life-threatening cutaneous reactions can occur with intravenous ceftriaxone, even in patients with no prior history of beta-lactam allergy. The intravenous route delivers the drug directly into systemic circulation, meaning hypersensitivity reactions can develop rapidly and with greater severity than with oral or intramuscular routes. A thorough allergy history covering all antibiotic exposures must be obtained before administration. Emergency resuscitation equipment including epinephrine, antihistamines, corticosteroids, airway management devices, and full cardiovascular resuscitation capability must be immediately available throughout the infusion and for a minimum observation period following completion. Any sign of hypersensitivity during infusion including flushing, urticaria, bronchospasm, hypotension, or angioedema requires immediate cessation of the infusion and prompt emergency management.
Ceftriaxone-Calcium Precipitation: This is a critical and potentially fatal drug incompatibility. Ceftriaxone must never be mixed with or co-administered through the same intravenous line as any calcium-containing intravenous solution including Ringer's lactate, Hartmann's solution, and total parenteral nutrition containing calcium. The combination forms insoluble ceftriaxone-calcium salt precipitates that deposit in the pulmonary vasculature and renal tubules, causing pulmonary infiltrates, respiratory failure, and acute kidney injury. Fatal cases have been documented, predominantly in neonates. In neonates, the combination of ceftriaxone with any calcium-containing preparation by any route at any time is absolutely contraindicated. In adults and older children, if both ceftriaxone and calcium-containing solutions are required, they must be administered through separate intravenous lines at different infusion sites, and sequential administration through the same line requires thorough flushing with a compatible solution between the two medications.
Bacterial Septicemia — Clinical Urgency: When used for bacterial septicemia, the timeliness of antibiotic administration is directly correlated with patient outcomes. Current sepsis management guidelines recommend antibiotic administration within one hour of sepsis recognition in patients with septic shock and within three hours in other sepsis presentations. Every hour of delay in effective antibiotic administration in septic shock is associated with a measurable increase in mortality. Blood cultures and other relevant microbiological specimens must be collected before antibiotic administration wherever clinically possible, but must never delay treatment in hemodynamically unstable patients.
Clostridium difficile-Associated Diarrhea and Colitis: Broad-spectrum cephalosporin use significantly disrupts the normal gastrointestinal microbiome and carries one of the higher risks among antibiotic classes for precipitating Clostridium difficile infection. Severity ranges from self-limiting mild diarrhea to fulminant pseudomembranous colitis with toxic megacolon, colonic perforation, and death. This complication can occur during treatment or weeks to months after antibiotic completion. New onset diarrhea in any patient during or following ceftriaxone therapy must prompt evaluation for Clostridium difficile. Antiperistaltic medications must be avoided in suspected Clostridium difficile colitis as they can precipitate toxic megacolon.
Infusion-Related Reactions and Phlebitis: Rapid intravenous bolus injection of ceftriaxone can cause pain, burning sensation, local phlebitis, and venous irritation along the infusion site. Ceftriaxone must always be administered by slow intravenous infusion over the recommended time period, typically 30 minutes, and never as a rapid bolus injection. Adequate dilution of the reconstituted solution before infusion and use of appropriate intravenous technique significantly reduces infusion site reactions. The intravenous line should be flushed with compatible solution before and after ceftriaxone administration.
Hemolytic Anemia: Immune-mediated hemolytic anemia, including severe and fatal cases, has been reported with ceftriaxone therapy. Hemolytic anemia can develop during treatment or shortly after completion. Patients developing unexplained pallor, progressive fatigue, jaundice, dark urine, or a significant unexplained drop in hemoglobin during or after therapy must be evaluated urgently for immune hemolytic anemia. Ceftriaxone must be stopped immediately if hemolytic anemia is confirmed or strongly suspected.
Biliary Complications and Pseudolithiasis: Ceftriaxone is excreted in high concentrations in bile and can form insoluble calcium-ceftriaxone precipitates in the gallbladder, causing biliary sludge and pseudolithiasis that may mimic symptomatic gallstone disease. This occurs more commonly with higher doses, longer treatment durations, and in patients with pre-existing biliary tract abnormalities or those receiving concurrent total parenteral nutrition. New onset right upper quadrant pain, nausea, or biliary colic during ceftriaxone therapy should be investigated with abdominal ultrasound. The precipitates typically resolve spontaneously following discontinuation.
Prolonged Prothrombin Time and Coagulopathy: Ceftriaxone and other cephalosporins can reduce intestinal vitamin K2 production by suppressing gut flora, potentially prolonging prothrombin time and increasing bleeding risk. This effect is most clinically significant in patients who are malnourished, have poor vitamin K dietary intake, are receiving prolonged therapy, or are concurrently taking warfarin or other anticoagulants. Prothrombin time should be monitored in at-risk patients and vitamin K supplementation considered where appropriate.
Seizures: Encephalopathy, myoclonus, and seizures have been reported with ceftriaxone, most commonly in patients with renal impairment receiving doses not appropriately adjusted for their level of kidney function. Use with caution in patients with epilepsy or a history of seizure disorders and monitor neurological status in patients with significant renal impairment.
Superinfection: Prolonged intravenous ceftriaxone therapy selects for resistant organisms and can lead to superinfection with resistant bacteria including extended-spectrum beta-lactamase producers, Pseudomonas aeruginosa, Enterococcus species, and Candida species. New fever, clinical deterioration, or microbiological evidence of a new pathogen during treatment should prompt reassessment of the antibiotic regimen.
Notify the attending medical team and initiate emergency management immediately if the patient develops signs of anaphylaxis during or following infusion including urticaria, bronchospasm, angioedema, hypotension, or cardiovascular collapse, shows signs of severe hemolytic anemia, develops signs of Clostridium difficile colitis including severe diarrhea, abdominal distension, or systemic toxicity, experiences biliary pain or jaundice during treatment, develops signs of superinfection or unexpected clinical deterioration despite treatment, shows unexpected neurological changes including seizures or encephalopathy, or develops signs of significant coagulopathy including unusual bleeding or bruising.
Consult Senior Medical Staff or Clinical Pharmacist Before Use In Patients Who Have:
A documented history of allergy to any cephalosporin or penicillin antibiotic, renal impairment of any severity where dose adjustment or extended dosing intervals may be required, hepatic impairment where reduced drug metabolism affects plasma levels, combined renal and hepatic impairment where accumulation risk is highest, a history of gastrointestinal disease particularly inflammatory bowel disease or prior Clostridium difficile infection, biliary tract disease or gallbladder abnormalities predisposing to ceftriaxone-related biliary complications, a history of seizure disorders or epilepsy, are neonates or premature infants where use carries specific and serious risks, are pregnant or breastfeeding, have pre-existing coagulopathy or are receiving anticoagulant therapy, are malnourished or have documented vitamin K deficiency, are receiving concurrent nephrotoxic medications, have febrile neutropenia where combination antibiotic coverage may be required, or are critically ill with multiple organ dysfunction where drug pharmacokinetics are significantly altered.
Common Side Effects
Oxidil IV Injection is generally well-tolerated when correctly prepared and administered by slow intravenous infusion. However, patients may experience infusion site reactions including pain, erythema, and phlebitis, diarrhea or loose stools, nausea, vomiting, abdominal discomfort, headache, elevated liver enzymes and bilirubin on blood tests, elevated blood urea or creatinine, skin rash, eosinophilia on blood count, and prolonged prothrombin time. In patients receiving prolonged courses, candidal superinfection of the oral cavity or genitourinary tract may develop.
Serious adverse effects requiring immediate medical intervention include anaphylaxis and severe hypersensitivity reactions, severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, immune hemolytic anemia including severe and fatal cases, Clostridium difficile pseudomembranous colitis, ceftriaxone-calcium precipitation causing pulmonary or renal complications, symptomatic biliary pseudolithiasis, seizures and encephalopathy, significant coagulopathy and bleeding, thrombocytopenia and neutropenia, and superinfection with resistant organisms or fungi.
Drug Interactions
A comprehensive medication review is essential before initiating intravenous ceftriaxone in any patient, particularly those in the inpatient setting receiving multiple concurrent medications. Clinically important interactions include those with calcium-containing intravenous solutions and preparations where concurrent use is absolutely contraindicated due to the risk of fatal precipitation particularly in neonates, warfarin and other anticoagulants where ceftriaxone enhances anticoagulant effect through vitamin K suppression requiring more frequent INR monitoring and potential dose adjustment, aminoglycoside antibiotics including gentamicin, amikacin, and tobramycin where the combination carries additive nephrotoxicity and ototoxicity risk and the two agents must never be mixed in the same solution or infusion bag, loop diuretics including furosemide where concurrent use increases the risk of nephrotoxicity particularly in patients with pre-existing renal impairment, probenecid which affects renal elimination of some beta-lactam antibiotics, oral contraceptives where broad-spectrum antibiotic therapy may theoretically reduce contraceptive effectiveness through alteration of gut flora and enterohepatic cycling, live bacterial vaccines including live oral typhoid vaccine where concurrent antibiotic therapy may impair vaccine efficacy and simultaneous use should be avoided, other nephrotoxic medications including amphotericin B, vancomycin, and non-steroidal anti-inflammatory drugs where concurrent use requires careful renal function monitoring, and any other medications being administered concurrently in the inpatient setting that require careful compatibility assessment before co-administration through shared intravenous lines.
How Oxidil IV Injection 250mg Is Administered
Oxidil IV Injection must only be prepared and administered by or under the direct supervision of trained healthcare professionals following established institutional protocols and the manufacturer's preparation instructions. It must never be self-administered outside of a supervised clinical setting.
Reconstitution and Dilution: Reconstitute the 250mg vial with the appropriate volume of compatible diluent as specified in the manufacturer's instructions. Compatible diluents for intravenous use include sodium chloride 0.9%, glucose 5%, and glucose 10% solutions. Never reconstitute or dilute with calcium-containing solutions. After initial reconstitution, the solution should be further diluted in the appropriate volume of compatible infusion fluid for intravenous administration. Inspect the reconstituted and diluted solution visually for particulate matter and discoloration before administration. Use only clear, colorless to pale yellow solutions without visible particles or cloudiness.
Standard Adult Dosing: For most severe infections, the recommended adult dose is 1-2g administered once daily or in equally divided doses twice daily by intravenous infusion. For bacterial meningitis, doses of up to 4g daily may be required. For septicemia and life-threatening infections, doses at the higher end of the range are typically employed. For surgical prophylaxis, a single dose of 1-2g is administered 30-90 minutes before the procedure. For gonorrhea, a single dose of 250-500mg is typically used. All dosing must be confirmed by the prescribing physician based on the specific indication, infection severity, patient weight, renal and hepatic function, and current clinical guidelines.
Pediatric Dosing: Dosing in children is weight-based, typically 50-100mg per kilogram per day depending on the indication, severity of infection, and patient age. For meningitis and other central nervous system infections, doses at the higher end of the weight-based range are required. Dosing must always be verified by the prescribing physician or clinical pharmacist and must never exceed recommended maximum daily doses for the specific indication. Particular care is required in neonates where ceftriaxone use carries specific risks and requires specialist oversight.
Administration Technique: Administer by slow intravenous infusion over 30 minutes in adults and over 60 minutes in neonates where use is considered appropriate under specialist supervision. Never administer as a rapid intravenous bolus injection. Flush the intravenous line thoroughly with compatible solution before and after ceftriaxone administration to prevent incompatibility reactions with other medications being administered through the same line. Do not mix ceftriaxone with other antibiotics or medications in the same infusion bag or syringe unless compatibility has been specifically verified.
Duration of Treatment: Treatment duration depends on the type, site, and severity of infection, the infecting organism and its sensitivity profile, and the patient's clinical response. Most serious infections require 7-14 days of parenteral therapy. Septicemia typically requires a minimum of 10-14 days. Meningitis requires 7-21 days depending on the causative organism. Bone and joint infections may require 4-6 weeks of total antibiotic therapy, of which the intravenous phase is followed by oral step-down therapy where appropriate. The treating physician must determine the appropriate duration based on clinical and microbiological response. Transition from intravenous to oral therapy should be considered as early as clinical stability allows, in keeping with antibiotic stewardship principles.
Based on our pharmacists' clinical observations, the most critical aspects of safe and effective Oxidil IV Injection administration are strict adherence to preparation, dilution, and infusion rate protocols, absolute avoidance of calcium-containing solutions in the same line or infusion bag, thorough medication reconciliation before each administration to identify and manage potential drug incompatibilities and interactions, vigilant monitoring of the infusion site and the patient's clinical status throughout the infusion, prompt recognition and escalation of any signs of hypersensitivity or adverse reaction, and proactive planning for transition to oral antibiotic therapy as soon as the patient's clinical condition permits to minimize the risks and costs associated with prolonged intravenous antibiotic administration.
What Healthcare Providers and Patients Need to Know
Bacterial Septicemia — A Medical Emergency: Bacterial septicemia and septic shock are among the most time-critical medical emergencies encountered in clinical practice. Intravenous ceftriaxone is frequently used as part of empirical broad-spectrum antibiotic coverage in the initial management of sepsis where gram-negative organisms are suspected or where coverage needs to include organisms within ceftriaxone's spectrum. Adherence to current sepsis bundles, including early blood cultures, lactate measurement, intravenous fluid resuscitation, and antibiotic administration within the recommended time windows, is directly associated with improved survival outcomes. De-escalation of antibiotic therapy to the narrowest effective spectrum should occur as soon as culture and sensitivity results are available to preserve antibiotic effectiveness and minimize adverse effects.
Antibiotic Stewardship: Ceftriaxone is a valuable and broad-spectrum third-generation cephalosporin whose clinical utility depends on preserving its effectiveness through judicious use. Prescribing should be guided by confirmed or strongly suspected bacterial infection, local antimicrobial resistance surveillance data, and current evidence-based guidelines. Where possible, therapy should be de-escalated based on culture and sensitivity results to a narrower-spectrum agent. Treatment duration should be the shortest proven effective for the specific indication. Indiscriminate use of broad-spectrum cephalosporins drives the emergence of extended-spectrum beta-lactamase-producing organisms and carbapenem-resistant Enterobacteriaceae, pathogens that pose a serious and growing threat to public health.
Culture and Sensitivity Testing: Appropriate specimens for microbiological culture and sensitivity testing including blood cultures, sputum, urine, wound swabs, or cerebrospinal fluid depending on the clinical presentation should be collected before the first dose of ceftriaxone wherever clinically possible. This information is essential for confirming the diagnosis, identifying the causative organism and its antibiotic susceptibility profile, enabling rational de-escalation or modification of therapy, and detecting treatment failure due to resistance. In hemodynamically unstable patients with suspected septicemia, specimen collection must not delay antibiotic administration.
Renal and Hepatic Impairment: Ceftriaxone undergoes dual elimination through biliary excretion and renal filtration, which provides pharmacokinetic resilience in patients with impairment of either system alone. In patients with isolated renal impairment, biliary excretion compensates to a meaningful degree, and dose adjustments are not generally required until renal function is severely reduced. In patients with isolated hepatic impairment, renal elimination increases compensatorily. However, in patients with combined severe renal and hepatic impairment, both excretory pathways are compromised and drug accumulation can occur, requiring dose adjustment and extended dosing intervals under specialist guidance.
Pregnancy and Breastfeeding: Ceftriaxone crosses the placental barrier and is detectable in fetal circulation, and is excreted in breast milk in small quantities. Available data do not suggest significant teratogenicity and ceftriaxone is used in pregnancy when the severity of bacterial infection makes treatment clearly necessary and no safer alternative is available. The clinical decision to use ceftriaxone in pregnancy must balance the risks of untreated serious bacterial infection against the theoretical risks of the medication to the fetus, and should involve the treating obstetrician. Breastfeeding mothers receiving ceftriaxone should discuss with their healthcare provider whether to temporarily suspend breastfeeding or whether continuation is considered safe for the nursing infant given the small amounts excreted in milk.
Storage and Handling Instructions
Store unreconstituted vials at room temperature below 25°C, protected from light and moisture. Keep in original packaging until immediately before preparation. Reconstituted and diluted solutions must be prepared using aseptic technique and used within the stability period specified in the product information, which varies according to the diluent used and storage temperature. Do not use vials that show signs of physical damage, compromised seal integrity, discoloration, cloudiness, or visible contamination. Dispose of all unused portions of reconstituted solution, empty vials, and sharps in accordance with institutional infection control policies and clinical waste disposal regulations. Keep out of reach of children.
Manufacturer Information
[Manufacturer name and details would be inserted here based on your specific product]
Regulatory Status: Oxidil IV Injection 250mg is a prescription-only medication for intravenous administration exclusively in clinical settings by or under the supervision of trained healthcare professionals. It is not available for self-administration or home use outside of supervised clinical programs.
Medical Review Notice: This product information should be reviewed by a licensed physician or clinical pharmacist with expertise in infectious disease, antimicrobial therapy, and intravenous drug administration to ensure accuracy and compliance with current clinical guidelines, local antimicrobial resistance patterns, and antibiotic stewardship principles. Clinical use must be guided by current evidence-based guidelines for the management of specific bacterial infections including septicemia, and informed by local microbiological surveillance and institutional antibiotic stewardship programs.
Last Updated: [Date would be inserted here]